Merckx Mireille, Vanden Broeck Davy, Benoy Ina, Depuydt Christophe, Weyers Steven, Arbyn Marc
aInternational Centre for Reproductive Health (ICRH), Ghent University bDepartment of Obstetrics and Gynaecology, Ghent University Hospital, Ghent cSonic Health Care/AML, Antwerp dUnit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.
Eur J Cancer Prev. 2015 Jul;24(4):340-2. doi: 10.1097/CEJ.0000000000000067.
Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.
自2007年起，比利时就已将人乳头瘤病毒（HPV）疫苗接种纳入医保范围，起初针对的是12至15岁的女孩，2008年扩大至18岁以下女孩。本研究评估了参与机会性宫颈癌筛查的25岁以下女性中HPV 16/18感染情况的变化趋势。在最年轻的组（15至19岁）中，HPV 16的感染率显著降低[相对风险（RR）=0.61，95%置信区间=0.39至0.95]，而HPV 18的感染率虽有所下降但不显著（RR=0.65，95%置信区间=0.29至1.48）。年长组的感染率没有显著变化。这些发现显示了HPV疫苗接种的早期效果，并证实了在实际生活环境中免疫接种的有效性。
